Literature DB >> 35074224

Targeting Alternative Splicing as Adjunctive Treatment in EML4-ALK v3a/b+ NSCLC: Knowing Our Socratic Paradox and Learning From Spinal Muscular Atrophy.

Misako Nagasaka1, Sai-Hong Ignatius Ou2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35074224     DOI： 10.1016/j.jtho.2021.11.010

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  2 in total

1.  Reliability analysis of exonic-breakpoint fusions identified by DNA sequencing for predicting the efficacy of targeted therapy in non-small cell lung cancer.

Authors:  Weihua Li; Rui Wan; Lei Guo; Geyun Chang; Dong Jiang; Lin Meng; Jianming Ying
Journal:  BMC Med       Date:  2022-05-10       Impact factor: 11.150

Review 2.  Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer.

Authors:  Savvas Papageorgiou; Sarah L Pashley; Laura O'Regan; Sam Khan; Richard Bayliss; Andrew M Fry
Journal:  Cancers (Basel)       Date:  2022-07-15       Impact factor: 6.575
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.